Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule

Capsid-like particles consisting of a hepatitis B core (HBc) protein have been studied for their potential as carriers for drug delivery systems (DDS). The hollow HBc particle, which is formed by the self-assembly of core proteins comprising 183 aa residues, has the ability to bind to various cells...

Full description

Bibliographic Details
Main Authors:	Nishimura, Yuya, Mimura, Wakiko, Mohamed Suffian, Izzat Fahimuddin, Amino, Tomokazu, Ishii, Jun, Ogino, Chiaki, Kondo, Akihiko
Format:	Article
Language:	English
Published:	Oxford University Press 2011
Subjects:	QH301 Biology QR355 Virology RM Therapeutics. Pharmacology RM300 Drugs and their action
Online Access:	http://irep.iium.edu.my/57366/ http://irep.iium.edu.my/57366/ http://irep.iium.edu.my/57366/1/Granting%20specificity%20for%20breast%20cancer%20cells%20using%20a%20hepatitis%20B%20core%20particle%20with%20a%20HER2-targeted%20affibody%20molecule.pdf

id	iium-57366
recordtype	eprints
spelling	iium-573662017-06-23T00:16:56Z http://irep.iium.edu.my/57366/ Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule Nishimura, Yuya Mimura, Wakiko Mohamed Suffian, Izzat Fahimuddin Amino, Tomokazu Ishii, Jun Ogino, Chiaki Kondo, Akihiko QH301 Biology QR355 Virology RM Therapeutics. Pharmacology RM300 Drugs and their action Capsid-like particles consisting of a hepatitis B core (HBc) protein have been studied for their potential as carriers for drug delivery systems (DDS). The hollow HBc particle, which is formed by the self-assembly of core proteins comprising 183 aa residues, has the ability to bind to various cells non-specifically via the action of an arginine-rich domain. In this study, we developed an engineered HBc particle that specifically recognises and targets human epidermal growth factor receptor-related 2 (HER2)-expressing breast cancer cells. To despoil the non-specific binding property of an HBc particle, we genetically deleted the C-terminal 150–183 aa part of the core protein that encodes the arginine-rich domain (ΔHBc). Then, we genetically inserted a ZHER2 affibody molecule into the 78–81 aa position of the core protein to confer the ability of target-cell-specific recognition. The constructed ZHER2-displaying HBc (ZHER2-ΔHBc) particle specifically recognised HER2-expressing SKBR3 and MCF-7 breast cancer cells. In addition, the ZHER2-ΔHBc particle exhibited different binding amounts in accordance with the HER2 expression levels of cancer cells. These results show that the display of other types of Affibody molecules on HBc particles would be an expandable strategy for targeting several kinds of cancer cells that would help enable a pinpoint DDS. Oxford University Press 2011-12-11 Article PeerReviewed application/pdf en http://irep.iium.edu.my/57366/1/Granting%20specificity%20for%20breast%20cancer%20cells%20using%20a%20hepatitis%20B%20core%20particle%20with%20a%20HER2-targeted%20affibody%20molecule.pdf Nishimura, Yuya and Mimura, Wakiko and Mohamed Suffian, Izzat Fahimuddin and Amino, Tomokazu and Ishii, Jun and Ogino, Chiaki and Kondo, Akihiko (2011) Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule. Journal of Biochemistry, 153 (3). pp. 251-256. ISSN 0021-924X E-ISSN 1756-2651 https://doi.org/10.1093/jb/mvs140
repository_type	Digital Repository
institution_category	Local University
institution	International Islamic University Malaysia
building	IIUM Repository
collection	Online Access
language	English
topic	QH301 Biology QR355 Virology RM Therapeutics. Pharmacology RM300 Drugs and their action
spellingShingle	QH301 Biology QR355 Virology RM Therapeutics. Pharmacology RM300 Drugs and their action Nishimura, Yuya Mimura, Wakiko Mohamed Suffian, Izzat Fahimuddin Amino, Tomokazu Ishii, Jun Ogino, Chiaki Kondo, Akihiko Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule
description	Capsid-like particles consisting of a hepatitis B core (HBc) protein have been studied for their potential as carriers for drug delivery systems (DDS). The hollow HBc particle, which is formed by the self-assembly of core proteins comprising 183 aa residues, has the ability to bind to various cells non-specifically via the action of an arginine-rich domain. In this study, we developed an engineered HBc particle that specifically recognises and targets human epidermal growth factor receptor-related 2 (HER2)-expressing breast cancer cells. To despoil the non-specific binding property of an HBc particle, we genetically deleted the C-terminal 150–183 aa part of the core protein that encodes the arginine-rich domain (ΔHBc). Then, we genetically inserted a ZHER2 affibody molecule into the 78–81 aa position of the core protein to confer the ability of target-cell-specific recognition. The constructed ZHER2-displaying HBc (ZHER2-ΔHBc) particle specifically recognised HER2-expressing SKBR3 and MCF-7 breast cancer cells. In addition, the ZHER2-ΔHBc particle exhibited different binding amounts in accordance with the HER2 expression levels of cancer cells. These results show that the display of other types of Affibody molecules on HBc particles would be an expandable strategy for targeting several kinds of cancer cells that would help enable a pinpoint DDS.
format	Article
author	Nishimura, Yuya Mimura, Wakiko Mohamed Suffian, Izzat Fahimuddin Amino, Tomokazu Ishii, Jun Ogino, Chiaki Kondo, Akihiko
author_facet	Nishimura, Yuya Mimura, Wakiko Mohamed Suffian, Izzat Fahimuddin Amino, Tomokazu Ishii, Jun Ogino, Chiaki Kondo, Akihiko
author_sort	Nishimura, Yuya
title	Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule
title_short	Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule
title_full	Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule
title_fullStr	Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule
title_full_unstemmed	Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule
title_sort	granting specificity for breast cancer cells using a hepatitis b core particle with a her2-targeted affibody molecule
publisher	Oxford University Press
publishDate	2011
url	http://irep.iium.edu.my/57366/ http://irep.iium.edu.my/57366/ http://irep.iium.edu.my/57366/1/Granting%20specificity%20for%20breast%20cancer%20cells%20using%20a%20hepatitis%20B%20core%20particle%20with%20a%20HER2-targeted%20affibody%20molecule.pdf
first_indexed	2023-09-18T21:21:06Z
last_indexed	2023-09-18T21:21:06Z
_version_	1777411886818525184

Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule

Similar Items